Dr. Kiran Mahajan (Ayurveda) needs a second opinion on this medical case.
The trial tested four repurposed drugs: Remdesivir, Interferon β1a, Lopinavir/Ritonavir and Hydroxychloroquine. Interim analysis showed that no benefits of Remdesivir in any groups of COVID-19 (asymptomatic /mild / moderate /severe /critical) patients. ICMR has succeeded in conducting this large randomized controlled study even during a pandemic situation and earlier lockdown. This study reliably answers to critical public health questions concerning therapeutics. Earlier, ICMR conducted PLACID trial for convalescent plasma indicating no benefit of it in COVID treatment.
See this content immediately after install